Molecular Partners AG balance sheet

At the end of fiscal 2025, Molecular Partners AG had total assets of $129m, total liabilities of $27.4m and shareholders' equity of $101m. It held $104m in cash against $0 of debt: net cash of $104m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Molecular Partners AG: balance sheet, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash and equivalents	78	151	79	95	80	70	104
Receivables	—	3	28	1	2	3	2
Total current assets	—	201	180	276	229	170	122
Total assets	—	212	189	284	236	175	129
Total current liabilities	—	65	51	19	17	12	14
Total debt	0	0	0	0	0	0	0
Total liabilities	—	91	71	29	26	19	27
Shareholders' equity	56	121	117	254	210	156	101
Net debt (negative = net cash)	−78	−151	−79	−95	−80	−70	−104
Shares outstanding	22m	29m	32m	36m	36m	40m	40m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Molecular Partners AG's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Molecular Partners AG.